Abstract
Gs and Gi are guanine nucleotide-binding, heterotrimer proteins that regulate the activity of adenylate cyclase, and are responsible for transferring stimulatory and inhibitory hormonal signals, respectively, from cell surface receptors to the enzyme catalytic unit1–3. These proteins can be directly activated by agents such as GTP and analogues, fluoride and magnesium2,4,5. Decreased amounts of Gs and Gi and even the absence of Gs, have been described6–9, whereas an altered Gs has been reported in a cultured cell line (UNC variant of S49 lymphoma cells10), but has never been observed in human disease states. We have found a profoundly altered Gs protein in a group of human growth hormone-secreting pituitary adenomas, characterized by high secretory activity and intracellular cyclic AMP levels. In the membranes from these tumours no stimulation of adenylate cyclase activity by growth hormone-releasing hormone, by GTP or by fluoride was observed. Indeed, the last two agents caused an inhibition, probably mediated by Gi. In contrast, adenylate cyclase stimulation by Mg2+ was enormously increased. This altered pattern of adenylate cyclase regulation was reproduced when a cholate extract of the tumour membranes (which contains G proteins) was reconstituted with Gs-free, cyc− S49 cell membranes. Inasmuch as secretion from somatotrophic cells is known to be a cAMP-dependent function11, the alteration of Gs could be the direct cause of the high secretory activity of the tumours in which it occurs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
1. Rodbell, M. Nature 284, 17–22 (1980). 2. Oilman, A. G. Cell 36, 577–579 (1984). 3. Oilman, A. G. Trends Neurosci. 9, 460–463 (1986). 4. Codina, J. et al. in Advances in Cyclic Nucleotide and Protein Phosphorylation Research Vol. 17 (eds Greengard, P., Robison, G. A., Paoletti, R. & Nicosia, S.) 111–125 (Raven, New York, 1986). 5. Codina, J., Hildebrandt, J. D., Birnbaumer, L. & Sekura, R. D. 7. bioi Chem. 259, 11408–11418 (1984). 6. Levine, M. A., Eil, C., Downs Jr, R. W. & Spiegel, A. M. J. din. Invest. 72, 316–324 (1983). 7. Hildebrandt, J. D. et al. Nature 302, 706–709 (1983). 8. Jakobs, K. H. & Schultz, G. Proc. natn. Acad. Sci. U.S.A. 80, 3899–3902 (1983). 9. Gawler, D., Milligan, G., Spiegel, A. M., Unson, C. G. & Houslay, M. D. Nature 327, 229–232 (1987). 10. Schleifer, L. S., Garrison, J. C., Sternweis, P. C., Northup, J. K. & Oilman, A. G. J. bioi Chem. 255, 2641–2644 (1980). 11. Spada, A., Vallar, L. & Giannattasio, G. Endocrinology 115, 1203–1209 (1984). 12. Rude, R. K., Baker, A. J. & Watts, R. B. Endocrinology 113, 1348–1355 (1983). 13. Oldham, S. B., Rude, R. K., Molloy, C. T., Lipson, L. G. & Boggs, T. T. Endocrinology 115, 1883–1890 (1984). 14. Bockaert, J., Cantau, B. & Sebben Perez, M. Molec. Pharmacol. 26, 180–186 (1984). 15. Seamon, K. B., Padgett, W. & Daly, J. W. Proc. natn. Acad. Sci. U.S.A. 78,3363–3367 (1981). 16. Yamashita, A., Kurokawa, T., Higashi, K., Danura, T. & Ishibashi, S. Biochem. biophys. Res. Commun. 137, 190–194 (1986). 17. Yamamura, H., Lad, P. M. & Rodbell, M. 7. bioi. Chem. 252, 7964–7966 (1977). 18. Steer, M. L. & Wood, A. 7. bioi Chem. 254, 10791–10797 (1979). 19. Spiegel A. M. & Downs, R. W. Jr Endocr. Rev. 2, 275–305 (1981). 20. Manganiello, V. C. & Vaughan, M. 7. bioi Chem. 251, 6205–6209 (1976). 21. Northup, J. K. et al. Proc. natn. Acad. Sci. U.S.A. 77, 6516–6520 (1980). 22. Moss, J. & Vaughan, M. A. Rev. Biochem. 48, 581–600 (1979). 23. Katada, T. & Ui, M. Proc. natn. Acad. Sci. U.S.A. 79, 3129–3133 (1982). 24. Kahn, R. A., Katada, T., Bokoch, G. M., Northup, J. K. & Oilman, A. G. in Post-Translational Covalent Modifications of Proteins (ed. Johnson, B. C. ) 373–395 (Academic, New York, 1983). 25. Katada, T., Bokoch, G. M., Northup, J. K., Ui, M. & Gilman, A. G. 7. bioi Chem. 259, 3568–3577 (1984). 26. Ui, M. Trends Pharmacol. Sci. 5, 277–279 (1984). 27. Robishaw, J. D., Smigel, M. D. & Gilman, A. G 7. bioi Chem. 261, 9587–9590 (1986). 28. Billestrup, N., Swanson, L. W. & Vale, W. Proc. natn. Acad. Sci. U.S.A. 83,6854–6857 (1986). 29. Ross, E. M., Maguire, M. E., Sturgill, T. W., Biltonen, R. L. & Gilman, A. G. 7. bioi Chem. 252, 5761–5775 (1977). 30. Rich, A. K. et al. J. bioi Chem. 259, 7893–7901 (1984). 31. Laemmli, U. K. Nature 227, 680–685 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vallar, L., Spada, A. & Giannattasio, G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas . Nature 330, 566–568 (1987). https://doi.org/10.1038/330566a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/330566a0
This article is cited by
-
Sporadic pituitary adenoma with somatic double-hit loss of MEN1
Pituitary (2023)
-
Global changes in chromatin accessibility and transcription in growth hormone-secreting pituitary adenoma
Endocrine (2022)
-
Novel somatic variants involved in biochemical activity of pure growth hormone-secreting pituitary adenoma without GNAS variant
Scientific Reports (2021)
-
Drug resistance in pituitary tumours: from cell membrane to intracellular signalling
Nature Reviews Endocrinology (2021)
-
The clinical aspects of pituitary tumour genetics
Endocrine (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.